Randomised clinical study: Discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 9, 2015, Pages 1082-1092

  Jharap, B ^a   Sandborn, W J ^b   Reinisch, W ^c,d   D'Haens, G ^e   Robinson, A M ^f   Wang, W ^f   Huang, B ^f   Lazar, A ^f   Thakkar, R B ^f   Colombel, J F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f ABBVIE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIGESTIVE TRACT ENDOSCOPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FECES ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SCORING SYSTEM; SYNDROME DELINEATION; ULCER HEALING; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DEFECATION; DRUG EFFECTS; ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; INTESTINE MUCOSA; PHYSIOLOGY; QUESTIONNAIRE; RECTUM; REMISSION; SELF REPORT; WOUND HEALING;

ADALIMUMAB; ANTIINFLAMMATORY AGENT;

ADALIMUMAB; ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; DEFECATION; ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTESTINAL MUCOSA; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; RECTUM; REMISSION INDUCTION; SELF REPORT; SURVEYS AND QUESTIONNAIRES; WOUND HEALING;

EID: 84942982258     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13387     Document Type: Article

References (34)

1. Reinisch W, Van Assche G, Befrits R, et al., Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis 2012; 6: 248-58.
2. D'Haens GR, Panaccione R, Higgins PD, et al., The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212.
3. Lichtenstein GR, Rutgeerts P,. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2010; 16: 338-46.
4. Colombel JF, Rutgeerts P, Reinisch W, et al., Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
5. Laharie D, Filippi J, Roblin X, et al., Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience. Aliment Pharmacol Ther 2013; 37: 998-1004.
6. Miyoshi J, Matsuoka K, Inoue N, et al., Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis 2013; 7: e609-14.
7. Ardizzone S, Cassinotti A, Duca P, et al., Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011; 9: 483-9.
8. Dignass A, Lindsay JO, Sturm A, et al., Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012; 6: 991-1030.
9. Gomollõn F, García-Lõpez S, Sicilia B, Gisbert JP, Hinojosa J,; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa. Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU. Gastroenterol Hepatol 2013; 36: 104-14.
10. Bouguen G, Levesque BG, Pola S, Evan E, Sanborn WJ,. Feasibility of endoscopic assessment and treating to target to achieve mucosal healing in ulcerative colitis. Inflamm Bowel Dis 2014; 20: 231-9.
11. Reinisch W, Sandborn WJ, Hommes DW, et al., Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
12. Reinisch W, Sandborn WJ, Panaccione R, et al., 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013; 19: 1700-9.
13. Sandborn WJ, van Assche G, Reinisch W, et al., Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-65.
14. Sandborn WJ, Colombel JF, D'Haens G, et al., One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 204-13.
15. Wikipedia. Sensitivity and specificity. http://en.wikipedia.org/wiki/Sensitivity-and-specificity. 2015.
16. Guyatt G, Mitchell A, Irvine EJ, et al., A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-10.
17. Reinisch W, Sandborn W, Feagan B, et al., Association between week eight Mayo subscores and hospitalization rates in adalimumab-treated patients with ulcerative colitis from ULTRA 1 and ULTRA 2 [abstract 1683]. Am J Gastroenterol 2013; 108 (Suppl 1s): S506.
18. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME,. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
19. Dick AP, Holt LP, Dalton ER,. Persistence of mucosal abnormality in ulcerative colitis. Gut 1966; 7: 355-60.
20. Rosenberg L, Lawlor GO, Zenlea T, et al., Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2013; 19: 779-84.
21. Christensen B, Erlich J, Hanauer SB, Rubin DT,. Agreement between deep histological remission and mucosal healing in ulcerative colitis and predictors of each outcome [abstract 964]. Gastroenterology 2014; 146 (Suppl. 1): S-172.
22. Vivinus-Nébot M, Frin G, Bzioueche H, et al., Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low grade inflammation [abstract Su2035]. Gastroenterology 2013; 144 (Suppl. 1): S-538.
23. Linden DR,. Colitis is associated with a loss of intestinofugal neurons. Am J Physiol Gastrointest Liver Physiol 2012; 303: G1096-104.
24. Rumessen JJ, Vanderwinden JM, Horn T,. Ulcerative colitis: ultrastructure of interstitial cells in myenteric plexus. Ultrastruct Pathol 2010; 34: 279-87.
25. Bernardini N, Segnani C, Ippolito C, et al., Immunohistochemical analysis of myenteric ganglia and interstitial cells of Cajal in ulcerative colitis. J Cell Mol Med 2012; 16: 318-27.
26. van Hoboken EA, Thijssen AY, Verhaaren R, et al., Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand J Gastroenterol 2011; 46: 981-7.
27. De Dombal FT, Geffen N, Darnborough A, Watkinson G, Goligher JC,. Radiological appearances of ulcerative colitis: an evaluation of their clinical significance. Gut 1968; 9: 157-63.
28. Keohane J, O'Mahony C, O'Mahony L, O'Mahony S, Quigley EM, Shanahan F,. Irritable bowel syndrome-like symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation. Am J Gastroenterol 2010; 105: 1789-94.
29. Schreiber S, Panés J, Louis E, Holley D, Buch M, Paridaens K,. Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey. BMC Gastroenterol 2012; 12: 108.
30. Feagan BG, Sandborn WJ, D'Haens G, et al., The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. Gastroenterology 2013; 145: 149-57.
31. Travis SP, Danese S, Kupcinskas L, et al., Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63: 433-41.
32. Kato J, Kuriyama M, Hiraoka S, Yamamoto K,. Is sigmoidoscopy sufficient for evaluating inflammatory status of ulcerative colitis patients? J Gastroenterol Hepatol 2011; 26: 683-7.
33. Colombel J-F, Ordás I, Ullman TA, et al., Comparison of rectosigmoidoscopy and colonoscopy for assessment of endoscopic activity in ulcerative colitis [abstract 1240]. Gastroenterology 2015; 148 (Suppl. 1): S-298.
34. Rhodes JM, Robinson R, Beales I, et al., Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther 2008; 27: 228-40.